# SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

Study · id `cardio:ct-nct05345327` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05345327](<https://clinicaltrials.gov/study/NCT05345327>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05345327

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 994 participants.

## Technical summary

Registry record NCT05345327. Randomized; quadruple masking; primary purpose prevention. Start 2023-01-01 (actual); primary completion 2026-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 994 participants (planned count; ClinicalTrials.gov record NCT05345327, source copy `cardio:ctgov-nct05345327-2024-12-20`, retrieved 2026-10-26)
- Started: 2023-01-01 (actual) (ClinicalTrials.gov record NCT05345327, source copy `cardio:ctgov-nct05345327-2024-12-20`, retrieved 2026-10-26)
- Primary completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT05345327, source copy `cardio:ctgov-nct05345327-2024-12-20`, retrieved 2026-10-26)
- Completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT05345327, source copy `cardio:ctgov-nct05345327-2024-12-20`, retrieved 2026-10-26)
- Countries: Australia; Sri Lanka (ClinicalTrials.gov record NCT05345327, source copy `cardio:ctgov-nct05345327-2024-12-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05345327-2024-12-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
- Acronym: START
- Condition: Type 2 Diabetes
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Metformin
- Lead sponsor: The George Institute
- Lead sponsor class: OTHER
- Collaborator: The University of New South Wales
- Collaborator class: OTHER
- Collaborator: Monash University
- Collaborator class: OTHER
- Collaborator: University of Sydney
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: The George Institute for Global Health (`core:george-institute`)
- Registry lists this organization as a collaborator: Monash University (`cardio:org-monash-university`)
- Registry lists this organization as a collaborator: University of Sydney (`cardio:org-university-of-sydney`)

## Provenance

Content hash: 393a37ad8f950602cc2196756ad72b1bed2a3240da2a2c6be7ef66618fc7135f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
